Wave Life Sciences/$WVE

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Wave Life Sciences

WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.

Ticker

$WVE
Primary listing

Industry

Pharmaceuticals

Headquarters

Singapore, Singapore

Employees

288

ISIN

SG9999014716

WVE Metrics

BasicAdvanced
$1.2B
-
-$0.77
-0.92
-

What the Analysts think about WVE

Analyst ratings (Buy, Hold, Sell) for Wave Life Sciences stock.

Bulls say / Bears say

Wave Life Sciences has initiated the INLIGHT clinical trial for WVE-007, targeting obesity through a novel GalNAc-siRNA approach, with clinical data expected in the second half of 2025. (Wave Life Sciences Press Release)
The company achieved the first-ever therapeutic RNA editing in humans with WVE-006 in the RestorAATion-2 trial for Alpha-1 Antitrypsin Deficiency, demonstrating significant increases in wild-type M-AAT protein levels. (Wave Life Sciences Press Release)
Analysts have shown confidence in Wave Life Sciences, with HC Wainwright reiterating a 'Buy' rating and a $22.00 price target, suggesting a potential upside of approximately 95.90% from the current stock price. (Ticker Report)
CEO Paul Bolno sold 169,025 shares of Wave Life Sciences stock in March 2025, which could be perceived negatively by investors. (American Banking and Market News)
The company reported a quarterly loss of $0.47 per share in Q3 2024, missing the Zacks Consensus Estimate of a loss of $0.28, indicating financial challenges. (StockInvest.us)
Wave Life Sciences' projected annual revenue is expected to decrease by 93.26%, raising concerns about the company's financial sustainability. (Nasdaq)
Data summarised monthly by Lightyear AI. Last updated on 12 Jul 2025.

WVE Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

WVE Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $WVE

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs